← All trials
NCT06587685
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Jan 15, 2026
- First posted
- Sep 19, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 472
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Prime Gene Therapeutics Co., Ltd.Lead sponsor
- Peking UniversityOfficial
- China Medical UniversityOfficial
- Shanxi Medical UniversityOfficial
- Nanchang UniversityOfficial
- Ningbo UniversityOfficial
- Nanyang Central HospitalOfficial
- Capital Medical UniversityOfficial
- Southern Medical UniversityOfficial
- Guangzhou Medical UniversityOfficial
- Fujian Medical UniversityOfficial
- Hebei UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.